Single-agent capecitabin maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer

被引：0
|
作者：
Xu, R. [1 ]
Yuhong, L. [1 ]
Huiyan, L. [1 ]
Wei, W. [2 ]
Zhiqiang, W. [1 ]
Xia, Y. [3 ]
Dong, M. [4 ]
Hua, W. Feng [1 ]
Dongsheng, Z. [1 ]
Daren, L. [5 ]
Chen, L. Yin [6 ]
Jun, J. [7 ]
Hua, H. Xiao [8 ]
Wen, P. Jie [9 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Med Oncol, Guangzhou 510275, Guangdong, Peoples R China
[2] First Peoples Hosp Foshan, Med Oncol, Foshan, Peoples R China
[3] Huizhou Cent Hosp, Med Oncol, Huizhou, Peoples R China
[4] Guangdong Gen Hosp, Med Oncol, Guangzhou, Guangdong, Peoples R China
[5] Jiangmen Cent Hosp, Med Oncol, Jiangmen, Peoples R China
[6] Shantou Univ, Coll Med, Canc Hosp, Med Oncol, Shantou, Peoples R China
[7] Dongguan Peoples Hosp, Med Oncol, Dongguan, Peoples R China
[8] Guangxi Med Univ, Tumor Hosp, Med Oncol, Nanning, Peoples R China
[9] Zhongshan Peoples Hosp, Med Oncol, Zhongshan, Peoples R China
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31049-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2127
引用
收藏
页码：S373 / S374
页数：2
相关论文
共 50 条
  • [21] XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
    Cassidy, J.
    Clarke, S.
    Diaz-Rubio, E.
    Scheithauer, W.
    Figer, A.
    Wong, R.
    Koski, S.
    Rittweger, K.
    Gilberg, F.
    Saltz, L.
    BRITISH JOURNAL OF CANCER, 2011, 105 (01) : 58 - 64
  • [22] Single-agent docetaxel (TXT) as first-line treatment in metastatic breast cancer (MBC)
    Guarneri, D.
    Ratti, R.
    Venturino, A.
    Addamo, G.
    Coccorullo, Z.
    Colloca, G.
    Campora, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] Single-agent paclitaxel as first-line treatment of metastatic breast cancer: The British experience
    Davidson, NG
    SEMINARS IN ONCOLOGY, 1996, 23 (05) : 6 - 10
  • [24] Bevacizumab plus XELOX as first-line therapy for patients with metastatic colorectal cancer
    Gaspar, E.
    Juarez Marroqui, A.
    Vicent, J.
    Llorca, C.
    Orts, D.
    Galan, A.
    Barrajon, E.
    Cervera Grau, J.
    Giner, V.
    Macia, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer
    Moosmann, Nicolas
    Heinemann, Volker
    CLINICAL COLORECTAL CANCER, 2008, 7 (02) : 110 - 117
  • [26] CETUXIMAB IN COMBINATION WITH XELIRI OR XELOX IN FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
    Ocvirk, Janja
    Rebersek, Martina
    Boc, Marko
    Mesti, Tanja
    Moltara, Maja Ebert
    ANNALS OF ONCOLOGY, 2011, 22 : v96 - v96
  • [27] First-line single-agent cetuximab in patients with advanced colorectal cancer
    Pessino, A.
    Artale, S.
    Sciallero, S.
    Guglielmi, A.
    Fornarini, G.
    Andreotti, I. C.
    Mammoliti, S.
    Comandini, D.
    Caprioni, F.
    Bennicelli, E.
    Andretta, V.
    Siena, S.
    Sobrero, A.
    ANNALS OF ONCOLOGY, 2008, 19 (04) : 711 - 716
  • [28] Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer
    Karacetin, D.
    Yalcin, B.
    Okten, B.
    Ozturk, S.
    Maral, O.
    Incekara, O.
    JOURNAL OF BUON, 2009, 14 (04): : 605 - 608
  • [29] PHARMACOECONOMIC ANALYSIS OF DIRECT MEDICAL COSTS OF METASTATIC COLORECTAL CANCER THERAPY WITH XELOX OR FOLFOX4 WITH OR WITHOUT BEVACIZUMAB AS THE FIRST-LINE TREATMENT
    Tikhomirova, A.
    Kulikov, A.
    Yagudina, R.
    VALUE IN HEALTH, 2010, 13 (07) : A267 - A267
  • [30] Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer
    Kamal, A. H.
    Camacho, F.
    Anderson, R.
    Wei, W.
    Balkrishnan, R.
    Kimmick, G.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (01) : 371 - 378
12345